Igenica Raises $14M in Series C Financing

Igenica_old_logoIgenica, Inc., a Burlingame, CA-based biotherapeutic company, raised $14m in Series C extension financing.

Backers include major current investors The Column Group, 5AM Ventures, OrbiMed and Third Rock Ventures.

Led by chief executive officer Mary Haak-Frendscho, Ph.D., and chairman David V. Goeddel, Ph.D., Igenica focuses on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer.

The company intends to use the funds to advance its IGN523 through early clinical trials aimed at safety and clinical activity assessments in acute myelogeneous leukemia and to continue to discover and develop new therapeutics.



Join the discussion